カテゴリー： Market Monitor Global, 世界, 医療/バイオ

医薬品用中間体CDMOのグローバル市場展望 2023年-2029年：低分子CDMO、高分子CDMO

◆英語タイトル：Pharmaceutical Intermediate CDMO Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23DC16187）

◆商品コード：MMG23DC16187
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年12月
◆ページ数：107
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の医薬品用中間体CDMO市場規模と予測を収録しています。・世界の医薬品用中間体CDMO市場：売上、2018年-2023年、2024年-2029年
・世界の医薬品用中間体CDMO市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の医薬品用中間体CDMO市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「低分子CDMO」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

医薬品用中間体CDMOのグローバル主要企業は、Cambrex、 WR Grace、 Esteve Química、 AGC Pharma Chemicals、 Evonik、 CordenPharma、 Otsuka Chemical、 Wavelength、 KBI Biopharma、 Chengda Pharmaceuticals、 Apeloa Pharmaceutical、 Xi'an Manareco New Materials、 Shenzhen Sungening Bio-technology、 Chengdu D-innovation Pharmaceutical、 Huateng Pharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、医薬品用中間体CDMOのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の医薬品用中間体CDMO市場：タイプ別、2018年-2023年、2024年-2029年
世界の医薬品用中間体CDMO市場：タイプ別市場シェア、2022年
・低分子CDMO、高分子CDMO

世界の医薬品用中間体CDMO市場：用途別、2018年-2023年、2024年-2029年
世界の医薬品用中間体CDMO市場：用途別市場シェア、2022年
・製薬会社、バイオテクノロジー会社、その他

世界の医薬品用中間体CDMO市場：地域・国別、2018年-2023年、2024年-2029年
世界の医薬品用中間体CDMO市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における医薬品用中間体CDMOのグローバル売上、2018年-2023年
・主要企業における医薬品用中間体CDMOのグローバル売上シェア、2022年
・主要企業における医薬品用中間体CDMOのグローバル販売量、2018年-2023年
・主要企業における医薬品用中間体CDMOのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Cambrex、 WR Grace、 Esteve Química、 AGC Pharma Chemicals、 Evonik、 CordenPharma、 Otsuka Chemical、 Wavelength、 KBI Biopharma、 Chengda Pharmaceuticals、 Apeloa Pharmaceutical、 Xi'an Manareco New Materials、 Shenzhen Sungening Bio-technology、 Chengdu D-innovation Pharmaceutical、 Huateng Pharma

*************************************************************

・調査・分析レポートの概要
医薬品用中間体CDMO市場の定義
市場セグメント
世界の医薬品用中間体CDMO市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の医薬品用中間体CDMO市場規模
世界の医薬品用中間体CDMO市場規模：2022年 VS 2029年
世界の医薬品用中間体CDMO市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの医薬品用中間体CDMOの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の医薬品用中間体CDMO製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：低分子CDMO、高分子CDMO
医薬品用中間体CDMOのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：製薬会社、バイオテクノロジー会社、その他
医薬品用中間体CDMOの用途別グローバル売上・予測

・地域別市場分析
地域別医薬品用中間体CDMO市場規模 2022年と2029年
地域別医薬品用中間体CDMO売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Cambrex、 WR Grace、 Esteve Química、 AGC Pharma Chemicals、 Evonik、 CordenPharma、 Otsuka Chemical、 Wavelength、 KBI Biopharma、 Chengda Pharmaceuticals、 Apeloa Pharmaceutical、 Xi'an Manareco New Materials、 Shenzhen Sungening Bio-technology、 Chengdu D-innovation Pharmaceutical、 Huateng Pharma
...

This research report provides a comprehensive analysis of the Pharmaceutical Intermediate CDMO market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Pharmaceutical Intermediate CDMO market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Pharmaceutical Intermediate CDMO, challenges faced by the industry, and potential opportunities for market players.
The global Pharmaceutical Intermediate CDMO market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Pharmaceutical Intermediate CDMO market presents opportunities for various stakeholders, including Pharmaceutical Company, Biotechnology Company. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Pharmaceutical Intermediate CDMO market. Additionally, the growing consumer demand present avenues for market expansion.
The global Pharmaceutical Intermediate CDMO market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Pharmaceutical Intermediate CDMO market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Pharmaceutical Intermediate CDMO market.
Market Overview: The report provides a comprehensive overview of the Pharmaceutical Intermediate CDMO market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Small Molecule Cdmo, Macromolecular Cdmo), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Pharmaceutical Intermediate CDMO market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Pharmaceutical Intermediate CDMO market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Pharmaceutical Intermediate CDMO market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Pharmaceutical Intermediate CDMO market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Pharmaceutical Intermediate CDMO market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Pharmaceutical Intermediate CDMO market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Pharmaceutical Intermediate CDMO, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Pharmaceutical Intermediate CDMO market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Pharmaceutical Intermediate CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Small Molecule Cdmo
Macromolecular Cdmo
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Others
Global Pharmaceutical Intermediate CDMO Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Cambrex
WR Grace
Esteve Química
AGC Pharma Chemicals
Evonik
CordenPharma
Otsuka Chemical
Wavelength
KBI Biopharma
Chengda Pharmaceuticals
Apeloa Pharmaceutical
Xi’an Manareco New Materials
Shenzhen Sungening Bio-technology
Chengdu D-innovation Pharmaceutical
Huateng Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pharmaceutical Intermediate CDMO, market overview.
Chapter 2: Global Pharmaceutical Intermediate CDMO market size in revenue.
Chapter 3: Detailed analysis of Pharmaceutical Intermediate CDMO company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pharmaceutical Intermediate CDMO in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Pharmaceutical Intermediate CDMO Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pharmaceutical Intermediate CDMO Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pharmaceutical Intermediate CDMO Overall Market Size
2.1 Global Pharmaceutical Intermediate CDMO Market Size: 2022 VS 2029
2.2 Global Pharmaceutical Intermediate CDMO Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Pharmaceutical Intermediate CDMO Players in Global Market
3.2 Top Global Pharmaceutical Intermediate CDMO Companies Ranked by Revenue
3.3 Global Pharmaceutical Intermediate CDMO Revenue by Companies
3.4 Top 3 and Top 5 Pharmaceutical Intermediate CDMO Companies in Global Market, by Revenue in 2022
3.5 Global Companies Pharmaceutical Intermediate CDMO Product Type
3.6 Tier 1, Tier 2 and Tier 3 Pharmaceutical Intermediate CDMO Players in Global Market
3.6.1 List of Global Tier 1 Pharmaceutical Intermediate CDMO Companies
3.6.2 List of Global Tier 2 and Tier 3 Pharmaceutical Intermediate CDMO Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Pharmaceutical Intermediate CDMO Market Size Markets, 2022 & 2029
4.1.2 Small Molecule Cdmo
4.1.3 Macromolecular Cdmo
4.2 By Type – Global Pharmaceutical Intermediate CDMO Revenue & Forecasts
4.2.1 By Type – Global Pharmaceutical Intermediate CDMO Revenue, 2018-2023
4.2.2 By Type – Global Pharmaceutical Intermediate CDMO Revenue, 2024-2029
4.2.3 By Type – Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Pharmaceutical Intermediate CDMO Market Size, 2022 & 2029
5.1.2 Pharmaceutical Company
5.1.3 Biotechnology Company
5.1.4 Others
5.2 By Application – Global Pharmaceutical Intermediate CDMO Revenue & Forecasts
5.2.1 By Application – Global Pharmaceutical Intermediate CDMO Revenue, 2018-2023
5.2.2 By Application – Global Pharmaceutical Intermediate CDMO Revenue, 2024-2029
5.2.3 By Application – Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Pharmaceutical Intermediate CDMO Market Size, 2022 & 2029
6.2 By Region – Global Pharmaceutical Intermediate CDMO Revenue & Forecasts
6.2.1 By Region – Global Pharmaceutical Intermediate CDMO Revenue, 2018-2023
6.2.2 By Region – Global Pharmaceutical Intermediate CDMO Revenue, 2024-2029
6.2.3 By Region – Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.3.2 US Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.3.3 Canada Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.3.4 Mexico Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.4.2 Germany Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.3 France Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.4 U.K. Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.5 Italy Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.6 Russia Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.7 Nordic Countries Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.8 Benelux Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.5.2 China Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5.3 Japan Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5.4 South Korea Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5.5 Southeast Asia Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5.6 India Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.6.2 Brazil Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.6.3 Argentina Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.7.2 Turkey Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.7.3 Israel Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.7.4 Saudi Arabia Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.7.5 UAE Pharmaceutical Intermediate CDMO Market Size, 2018-2029
7 Pharmaceutical Intermediate CDMO Companies Profiles
7.1 Cambrex
7.1.1 Cambrex Company Summary
7.1.2 Cambrex Business Overview
7.1.3 Cambrex Pharmaceutical Intermediate CDMO Major Product Offerings
7.1.4 Cambrex Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.1.5 Cambrex Key News & Latest Developments
7.2 WR Grace
7.2.1 WR Grace Company Summary
7.2.2 WR Grace Business Overview
7.2.3 WR Grace Pharmaceutical Intermediate CDMO Major Product Offerings
7.2.4 WR Grace Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.2.5 WR Grace Key News & Latest Developments
7.3 Esteve Química
7.3.1 Esteve Química Company Summary
7.3.2 Esteve Química Business Overview
7.3.3 Esteve Química Pharmaceutical Intermediate CDMO Major Product Offerings
7.3.4 Esteve Química Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.3.5 Esteve Química Key News & Latest Developments
7.4 AGC Pharma Chemicals
7.4.1 AGC Pharma Chemicals Company Summary
7.4.2 AGC Pharma Chemicals Business Overview
7.4.3 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Major Product Offerings
7.4.4 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.4.5 AGC Pharma Chemicals Key News & Latest Developments
7.5 Evonik
7.5.1 Evonik Company Summary
7.5.2 Evonik Business Overview
7.5.3 Evonik Pharmaceutical Intermediate CDMO Major Product Offerings
7.5.4 Evonik Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.5.5 Evonik Key News & Latest Developments
7.6 CordenPharma
7.6.1 CordenPharma Company Summary
7.6.2 CordenPharma Business Overview
7.6.3 CordenPharma Pharmaceutical Intermediate CDMO Major Product Offerings
7.6.4 CordenPharma Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.6.5 CordenPharma Key News & Latest Developments
7.7 Otsuka Chemical
7.7.1 Otsuka Chemical Company Summary
7.7.2 Otsuka Chemical Business Overview
7.7.3 Otsuka Chemical Pharmaceutical Intermediate CDMO Major Product Offerings
7.7.4 Otsuka Chemical Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.7.5 Otsuka Chemical Key News & Latest Developments
7.8 Wavelength
7.8.1 Wavelength Company Summary
7.8.2 Wavelength Business Overview
7.8.3 Wavelength Pharmaceutical Intermediate CDMO Major Product Offerings
7.8.4 Wavelength Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.8.5 Wavelength Key News & Latest Developments
7.9 KBI Biopharma
7.9.1 KBI Biopharma Company Summary
7.9.2 KBI Biopharma Business Overview
7.9.3 KBI Biopharma Pharmaceutical Intermediate CDMO Major Product Offerings
7.9.4 KBI Biopharma Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.9.5 KBI Biopharma Key News & Latest Developments
7.10 Chengda Pharmaceuticals
7.10.1 Chengda Pharmaceuticals Company Summary
7.10.2 Chengda Pharmaceuticals Business Overview
7.10.3 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Major Product Offerings
7.10.4 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.10.5 Chengda Pharmaceuticals Key News & Latest Developments
7.11 Apeloa Pharmaceutical
7.11.1 Apeloa Pharmaceutical Company Summary
7.11.2 Apeloa Pharmaceutical Business Overview
7.11.3 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Major Product Offerings
7.11.4 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.11.5 Apeloa Pharmaceutical Key News & Latest Developments
7.12 Xi’an Manareco New Materials
7.12.1 Xi’an Manareco New Materials Company Summary
7.12.2 Xi’an Manareco New Materials Business Overview
7.12.3 Xi’an Manareco New Materials Pharmaceutical Intermediate CDMO Major Product Offerings
7.12.4 Xi’an Manareco New Materials Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.12.5 Xi’an Manareco New Materials Key News & Latest Developments
7.13 Shenzhen Sungening Bio-technology
7.13.1 Shenzhen Sungening Bio-technology Company Summary
7.13.2 Shenzhen Sungening Bio-technology Business Overview
7.13.3 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Major Product Offerings
7.13.4 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.13.5 Shenzhen Sungening Bio-technology Key News & Latest Developments
7.14 Chengdu D-innovation Pharmaceutical
7.14.1 Chengdu D-innovation Pharmaceutical Company Summary
7.14.2 Chengdu D-innovation Pharmaceutical Business Overview
7.14.3 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Major Product Offerings
7.14.4 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.14.5 Chengdu D-innovation Pharmaceutical Key News & Latest Developments
7.15 Huateng Pharma
7.15.1 Huateng Pharma Company Summary
7.15.2 Huateng Pharma Business Overview
7.15.3 Huateng Pharma Pharmaceutical Intermediate CDMO Major Product Offerings
7.15.4 Huateng Pharma Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.15.5 Huateng Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Pharmaceutical Intermediate CDMO Market Opportunities & Trends in Global Market
Table 2. Pharmaceutical Intermediate CDMO Market Drivers in Global Market
Table 3. Pharmaceutical Intermediate CDMO Market Restraints in Global Market
Table 4. Key Players of Pharmaceutical Intermediate CDMO in Global Market
Table 5. Top Pharmaceutical Intermediate CDMO Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Pharmaceutical Intermediate CDMO Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Pharmaceutical Intermediate CDMO Revenue Share by Companies, 2018-2023
Table 8. Global Companies Pharmaceutical Intermediate CDMO Product Type
Table 9. List of Global Tier 1 Pharmaceutical Intermediate CDMO Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Pharmaceutical Intermediate CDMO Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Pharmaceutical Intermediate CDMO Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Pharmaceutical Intermediate CDMO Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Pharmaceutical Intermediate CDMO Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Pharmaceutical Intermediate CDMO Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Pharmaceutical Intermediate CDMO Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Pharmaceutical Intermediate CDMO Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2024-2029
Table 30. Cambrex Company Summary
Table 31. Cambrex Pharmaceutical Intermediate CDMO Product Offerings
Table 32. Cambrex Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 33. Cambrex Key News & Latest Developments
Table 34. WR Grace Company Summary
Table 35. WR Grace Pharmaceutical Intermediate CDMO Product Offerings
Table 36. WR Grace Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 37. WR Grace Key News & Latest Developments
Table 38. Esteve Química Company Summary
Table 39. Esteve Química Pharmaceutical Intermediate CDMO Product Offerings
Table 40. Esteve Química Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 41. Esteve Química Key News & Latest Developments
Table 42. AGC Pharma Chemicals Company Summary
Table 43. AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Product Offerings
Table 44. AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 45. AGC Pharma Chemicals Key News & Latest Developments
Table 46. Evonik Company Summary
Table 47. Evonik Pharmaceutical Intermediate CDMO Product Offerings
Table 48. Evonik Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 49. Evonik Key News & Latest Developments
Table 50. CordenPharma Company Summary
Table 51. CordenPharma Pharmaceutical Intermediate CDMO Product Offerings
Table 52. CordenPharma Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 53. CordenPharma Key News & Latest Developments
Table 54. Otsuka Chemical Company Summary
Table 55. Otsuka Chemical Pharmaceutical Intermediate CDMO Product Offerings
Table 56. Otsuka Chemical Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 57. Otsuka Chemical Key News & Latest Developments
Table 58. Wavelength Company Summary
Table 59. Wavelength Pharmaceutical Intermediate CDMO Product Offerings
Table 60. Wavelength Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 61. Wavelength Key News & Latest Developments
Table 62. KBI Biopharma Company Summary
Table 63. KBI Biopharma Pharmaceutical Intermediate CDMO Product Offerings
Table 64. KBI Biopharma Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 65. KBI Biopharma Key News & Latest Developments
Table 66. Chengda Pharmaceuticals Company Summary
Table 67. Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Product Offerings
Table 68. Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 69. Chengda Pharmaceuticals Key News & Latest Developments
Table 70. Apeloa Pharmaceutical Company Summary
Table 71. Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Product Offerings
Table 72. Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 73. Apeloa Pharmaceutical Key News & Latest Developments
Table 74. Xi'an Manareco New Materials Company Summary
Table 75. Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Product Offerings
Table 76. Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 77. Xi'an Manareco New Materials Key News & Latest Developments
Table 78. Shenzhen Sungening Bio-technology Company Summary
Table 79. Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Product Offerings
Table 80. Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 81. Shenzhen Sungening Bio-technology Key News & Latest Developments
Table 82. Chengdu D-innovation Pharmaceutical Company Summary
Table 83. Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Product Offerings
Table 84. Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 85. Chengdu D-innovation Pharmaceutical Key News & Latest Developments
Table 86. Huateng Pharma Company Summary
Table 87. Huateng Pharma Pharmaceutical Intermediate CDMO Product Offerings
Table 88. Huateng Pharma Pharmaceutical Intermediate CDMO Revenue (US$, Mn) & (2018-2023)
Table 89. Huateng Pharma Key News & Latest Developments
List of Figures
Figure 1. Pharmaceutical Intermediate CDMO Segment by Type in 2022
Figure 2. Pharmaceutical Intermediate CDMO Segment by Application in 2022
Figure 3. Global Pharmaceutical Intermediate CDMO Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Pharmaceutical Intermediate CDMO Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Pharmaceutical Intermediate CDMO Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Pharmaceutical Intermediate CDMO Revenue in 2022
Figure 8. By Type - Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 9. By Application - Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 10. By Type - Global Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 12. By Application - Global Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 14. By Region - Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 15. By Country - North America Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 16. US Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 20. Germany Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 21. France Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 28. China Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 32. India Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 34. Brazil Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
Figure 37. Turkey Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Pharmaceutical Intermediate CDMO Revenue, (US$, Mn), 2018-2029
Figure 41. Cambrex Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. WR Grace Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Esteve Química Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Evonik Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. CordenPharma Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Otsuka Chemical Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Wavelength Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. KBI Biopharma Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Huateng Pharma Pharmaceutical Intermediate CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 医薬品用中間体CDMOのグローバル市場展望 2023年-2029年：低分子CDMO、高分子CDMO(Pharmaceutical Intermediate CDMO Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

医薬品用中間体CDMOのグローバル市場展望 2023年-2029年：低分子CDMO、高分子CDMO

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp